Effectiveness of 2 and 3 mRNA COVID-19 Vaccines Doses against Omicron and Delta-Related Outpatient Illness among Adults, October 2021 - February 2022

Sara Kim; Jessie Chung; Keipp Talbot; Carlos G Grijalva; Karen Wernli; Erika Kiniry; Emily Toth Martin; Arnold Monto; Edward Belongia; Huong Q McLean; Manjusha Gaglani; Mufaddal Mamawala; Mary Patricia Nowalk; Krissy Moehling Geffel; Sara Tartof; Ana Florea; Justin S Lee; Mark W Tenforde; Manish Patel; Brendan Flannery.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22273535

Documentos relacionados

  1. Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022.
  2. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
  3. BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
  4. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
  5. Post-COVID Syndrome: The Stranger Ghost of Culprit COVID-19.
  6. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.
  7. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
  8. Smell Outcome and Seropositivity Titre in Post-COVID-19 Patients.
  9. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
  10. Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, Canada.